Intravenous or subcutaneous natalizumab in patients with relapsing –remitting multiple sclerosis: investigation on efficiency and savings—the EASIER study
ConclusionsSC natalizumab administration will consistently reduce consumption of patient and HCP times per procedure and associated costs.
Source: Journal of Neurology - Category: Neurology Source Type: research
More News: Brain | Information Technology | Italy Health | Multiple Sclerosis | Neurology | Nurses | Nursing | Study | Tysabri